# Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Study · id `cardio:ct-nct06814145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06814145](<https://clinicaltrials.gov/study/NCT06814145>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06814145

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 440 participants.

## Technical summary

Registry record NCT06814145. Randomized; no masking; primary purpose treatment. Start 2025-04-16 (actual); primary completion 2035-08-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 440 participants (planned count; ClinicalTrials.gov record NCT06814145, source copy `cardio:ctgov-nct06814145-2026-07-22`, retrieved 2026-10-31)
- Started: 2025-04-16 (actual) (ClinicalTrials.gov record NCT06814145, source copy `cardio:ctgov-nct06814145-2026-07-22`, retrieved 2026-10-31)
- Primary completion: 2035-08-10 (anticipated) (ClinicalTrials.gov record NCT06814145, source copy `cardio:ctgov-nct06814145-2026-07-22`, retrieved 2026-10-31)
- Completion: 2035-08-10 (anticipated) (ClinicalTrials.gov record NCT06814145, source copy `cardio:ctgov-nct06814145-2026-07-22`, retrieved 2026-10-31)
- Countries: United States; Belgium; Canada; France; Germany; Israel; Italy; Mexico; Poland; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT06814145, source copy `cardio:ctgov-nct06814145-2026-07-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06814145-2026-07-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
- Acronym: HARMONIZE
- Condition: Hypertension, Pulmonary
- Intervention (Biological): Sotatercept
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 7527f97b8a76353350380c492159ef2d83fbd9a1f24c677f62c70c8570cee009
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
